PRESS RELEASE published on 09/18/2024 at 07:14, 2 months 3 days ago Inside Information / Operations of the issuer (acquisitions, sales...) CARMAT launches a capital increase of €10.3 million, extendable up to €13.6 million, with a subscription price of €1.60 per share to fund activities until at least 2024. Offering includes priority period for shareholders and global placement Financial Structure Capital Increase Subscription Price CARMAT Global Placement
PRESS RELEASE published on 09/06/2024 at 07:00, 2 months 15 days ago Inside Information / News release on accounts, results CARMAT announces its 2024 half-year results, including €3.3M in sales, 20 Aeson® artificial heart implants, and reduction in cash-burn. The company also plans to achieve annual sales of €8-12M in 2024 and explores financing options Sales Financing CARMAT 2024 Results Aeson Heart
PRESS RELEASE published on 09/06/2024 at 07:00, 2 months 15 days ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
BRIEF published on 09/03/2024 at 19:49, 2 months 17 days ago Status of voting rights and capital of the company CARMAT Share Capital Voting Rights Equitization CARMAT Actions PACEO Financing
BRIEF published on 08/21/2024 at 18:05, 2 months 30 days ago Modification of the Rights Attached to the Categories of CARMAT Shares Share Capital Funding Action Right To Vote CARMAT
BRIEF published on 07/09/2024 at 07:05, 4 months 12 days ago CARMAT boosts its sales and affirms its development Business Development CARMAT Aeson® Locations EFICAS Study
PRESS RELEASE published on 07/09/2024 at 07:00, 4 months 12 days ago Inside Information / Other news releases CARMAT exceeds 2023 sales, with €3.2M revenue in H1 2024 & 20 Aeson® heart implants. Confidence in growth outlook maintained. EFICAS study progressing well Financial Results Sales Momentum CARMAT EFICAS Study Aeson Heart Implants
BRIEF published on 07/08/2024 at 07:05, 4 months 13 days ago CARMAT to Provide Half-Year Update on July 9, 2024 Financial Update CARMAT Artificial Heart Videoconference
PRESS RELEASE published on 07/08/2024 at 07:00, 4 months 13 days ago Inside Information / Other news releases CARMAT to provide a half-year update and host a videoconference in French on July 9, 2024. The update will cover advancements of the Aeson artificial heart and key company developments CARMAT Aeson Artificial Heart Videoconference Half-year Update Therapeutic Alternative
BRIEF published on 06/25/2024 at 07:05, 4 months 26 days ago New governance at CARMAT Governance Nomination Heart Failure CARMAT Pierre Bastid
Published on 11/21/2024 at 10:03, 35 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 38 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 38 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 3 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 13 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 33 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 36 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 38 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 38 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 37 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 40 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 18 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo